AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
DETERMINATIONS OF LEVELS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA - REASSESSMENT OF PARAMETERS AFFECTING ASSAY OUTCOME
Authors: LEW J REICHELDERFER P FOWLER M BREMER J CARROL R CASSOL S CHERNOFF D COOMBS R CRONIN M DICKOVER R FISCUS S HERMAN S JACKSON B KORNEGAY J KOVACS A MCINTOSH K MEYER W MICHAEL N MOFENSON L MOYE J QUINN T ROBB M VAHEY M WEISER B YEGHIAZARIAN T
Citation: J. Lew et al., DETERMINATIONS OF LEVELS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA - REASSESSMENT OF PARAMETERS AFFECTING ASSAY OUTCOME, Journal of clinical microbiology, 36(6), 1998, pp. 1471-1479
INCREASED TRANSMISSION OF VERTICAL HEPATITIS-C VIRUS (HCV) INFECTION TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-INFECTED INFANTS OF HIV- AND HCV-COINFECTED WOMEN
Authors: PAPAEVANGELOU V POLLACK H ROCHFORD G KOKKA R HOU ZY CHERNOFF D HANNA B KRASINSKI K BORKOWSKY W
Citation: V. Papaevangelou et al., INCREASED TRANSMISSION OF VERTICAL HEPATITIS-C VIRUS (HCV) INFECTION TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-INFECTED INFANTS OF HIV- AND HCV-COINFECTED WOMEN, The Journal of infectious diseases, 178(4), 1998, pp. 1047-1052
PROINFLAMMATORY CYTOKINE AND HUMAN-IMMUNODEFICIENCY-VIRUS RNA LEVELS DURING EARLY MYCOBACTERIUM-AVIUM COMPLEX BACTEREMIA IN ADVANCED AIDS
Authors: HAAS DW LEDERMAN MM CLOUGH LA WALLIS RS CHERNOFF D CRAMPTON SL
Citation: Dw. Haas et al., PROINFLAMMATORY CYTOKINE AND HUMAN-IMMUNODEFICIENCY-VIRUS RNA LEVELS DURING EARLY MYCOBACTERIUM-AVIUM COMPLEX BACTEREMIA IN ADVANCED AIDS, The Journal of infectious diseases, 177(6), 1998, pp. 1746-1749
CORRELATION OF VIRUS LOAD IN PLASMA AND LYMPH-NODE TISSUE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Authors: HARRIS M PATENAUDE P COOPERBERG P FILIPENKO D THORNE A RABOUD J RAE S DAILEY P CHERNOFF D TODD J CONWAY B MONTANER JSG
Citation: M. Harris et al., CORRELATION OF VIRUS LOAD IN PLASMA AND LYMPH-NODE TISSUE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, The Journal of infectious diseases, 176(5), 1997, pp. 1388-1392
LONGITUDINAL ANALYSIS OF QUANTITATIVE VIROLOGICAL MEASURES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 CD4 LYMPHOCYTES - IMPLICATIONS FOR APPLYING MEASUREMENTS TO INDIVIDUAL PATIENTS
Authors: PAXTON WB COOMBS RW MCELRATH MJ KEEFER MC HUGHES J SINANGIL F CHERNOFF D DEMETER L WILLIAMS B COREY L
Citation: Wb. Paxton et al., LONGITUDINAL ANALYSIS OF QUANTITATIVE VIROLOGICAL MEASURES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 CD4 LYMPHOCYTES - IMPLICATIONS FOR APPLYING MEASUREMENTS TO INDIVIDUAL PATIENTS, The Journal of infectious diseases, 175(2), 1997, pp. 247-254
INFLUENZA VACCINATION HAS NO EFFECT ON VIRAL LOAD IN HIV-INFECTED PATIENTS WITH HIGHER CD4 COUNTS
Authors: REBOLI AC PALMER A BYRNE B MCCOY P CHERNOFF D BAXTER JD
Citation: Ac. Reboli et al., INFLUENZA VACCINATION HAS NO EFFECT ON VIRAL LOAD IN HIV-INFECTED PATIENTS WITH HIGHER CD4 COUNTS, Clinical infectious diseases, 23(4), 1996, pp. 257-257
VIROLOGIC IMMUNOLOGIC EFFECTS OF INFLUENZA IMMUNIZATION ON HIV-1-INFECTED PATIENTS/
Authors: DAMICO R FOWKE K CHERNOFF D POTTAGE J BENSON C SHA B LANDAY A SHEARER G KESSLER H
Citation: R. Damico et al., VIROLOGIC IMMUNOLOGIC EFFECTS OF INFLUENZA IMMUNIZATION ON HIV-1-INFECTED PATIENTS/, Clinical infectious diseases, 23(4), 1996, pp. 258-258
THE USE OF BRANCHED DNA (BDNA) ASSAYS TO MONITOR THE CLINICAL COURSE OF HIV AND HEPATITIS-C INFECTIONS
Authors: WILBER J CHERNOFF D DETMER J KOLBERG J HENDRICKS D KERN D SANCHEZPESCADOR R TODD J ZANKI S URDEA M
Citation: J. Wilber et al., THE USE OF BRANCHED DNA (BDNA) ASSAYS TO MONITOR THE CLINICAL COURSE OF HIV AND HEPATITIS-C INFECTIONS, Biologicals, 24(3), 1996, pp. 217-217
SAFETY AND IMMUNOGENICITY OF ENV-2-3, A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE, IN COMBINATION WITH A NOVEL ADJUVANT, MTP-PEMF59/
Authors: KEEFER MC GRAHAM BS MCELRATH MJ MATTHEWS TJ STABLEIN DM COREY L WRIGHT PF LAWRENCE D FAST PE WEINHOLD K HSIEH RH CHERNOFF D DEKKER C DOLIN R
Citation: Mc. Keefer et al., SAFETY AND IMMUNOGENICITY OF ENV-2-3, A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE, IN COMBINATION WITH A NOVEL ADJUVANT, MTP-PEMF59/, AIDS research and human retroviruses, 12(8), 1996, pp. 683-693
THERAPEUTIC VACCINATION - A RANDOMIZED CONTROLLED-STUDY OF THE EFFECTOF RGP160 ON PROGRESSION OF IMMUNE-DEFICIENCY AND VIRAL BURDEN
Authors: TSOUKAS CM RABOUD J BERNARD N DJURDJEV O CASSOL S CHERNOFF D FONG I FREEDMAN J GILL J GOLDBERG E LAFRENIERE R LEE S MONTANER J POON MC RACHLIS A SCHLECH W SMITH G SZABO J TODD J THOMAS R VOLVOVITZ F
Citation: Cm. Tsoukas et al., THERAPEUTIC VACCINATION - A RANDOMIZED CONTROLLED-STUDY OF THE EFFECTOF RGP160 ON PROGRESSION OF IMMUNE-DEFICIENCY AND VIRAL BURDEN, AIDS, 10, 1996, pp. 62-62
PLASMA VIREMIA IS MORE PREDICTIVE OF DISEASE PROGRESSION THAN CD4 COUNTS IN HIV-INFECTED INDIVIDUALS WITH CD4 COUNTS GREATER-THAN 500 IN A RANDOMIZED TRIAL OF IMMUNIZATION WITH RGP160
Authors: JANET R TSOUKAS C BERNARD N DJURDJEV O CASSOL S CHERNOFF D FONG I FREEDMAN J GILL J GOLDBERG E LAFRENIERE R LEE S MONTANER J POON MC RACHLIS A SCHLECH W SMITH G SZABO J TODD J THOMAS R VOLVOVITZ F
Citation: R. Janet et al., PLASMA VIREMIA IS MORE PREDICTIVE OF DISEASE PROGRESSION THAN CD4 COUNTS IN HIV-INFECTED INDIVIDUALS WITH CD4 COUNTS GREATER-THAN 500 IN A RANDOMIZED TRIAL OF IMMUNIZATION WITH RGP160, AIDS, 10, 1996, pp. 63-63
CORRELATION OF VIRAL LOAD IN PLASMA AND LYMPH-NODE TISSUE IN PATIENTSUNDERGOING COMBINATION ANTIRETROVIRAL THERAPY
Authors: HARRIS M PATENAUDE P COOPERBERG P FILIPENKO D RABOUD J DAILEY P CHERNOFF D TODD J CONWAY B MONTANER JSG
Citation: M. Harris et al., CORRELATION OF VIRAL LOAD IN PLASMA AND LYMPH-NODE TISSUE IN PATIENTSUNDERGOING COMBINATION ANTIRETROVIRAL THERAPY, AIDS, 10, 1996, pp. 73-73
REAL-TIME SIMULATION FOR X-RAY-MICROANALYSIS
Authors: BRUNDLE D URITSKY Y CHERNOFF D
Citation: D. Brundle et al., REAL-TIME SIMULATION FOR X-RAY-MICROANALYSIS, Solid state technology, 39(3), 1996, pp. 105
SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL
Authors: GRAHAM BS KEEFER MC MCELRATH MJ GORSE GJ SCHWARTZ DH WEINHOLD K MATTHEWS TJ ESTERLITZ JR SINANGIL F FAST PE WRIGHT PF DOLIN R COREY L BELSHE RB CLEMENTS ML BOLOGNESI DP STABLEIN DM CHERNOFF D DULIEGE AM WALKER CM
Citation: Bs. Graham et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL, Annals of internal medicine, 125(4), 1996, pp. 270
PERFORMANCE-CHARACTERISTICS FOR THE QUANTITATION OF PLASMA HIV-1 RNA USING BRANCHED DNA SIGNAL AMPLIFICATION TECHNOLOGY
Authors: TODD J PACHL C WHITE R YEGHIAZARIAN T JOHNSON P TAYLOR B HOLODNIY M KERN D HAMREN S CHERNOFF D URDEA M
Citation: J. Todd et al., PERFORMANCE-CHARACTERISTICS FOR THE QUANTITATION OF PLASMA HIV-1 RNA USING BRANCHED DNA SIGNAL AMPLIFICATION TECHNOLOGY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 35-44
QUANTITATION OF HIV-1 RNA IN PLASMA USING BRANCHED DNA (BDNA) - EFFECT OF PATIENT BIOLOGIC VARIATION AND SPECIMEN MATRIX
Authors: PACHL C JUDSON B YEGHIAZARIAN T JOHNSON P BESEMER D WHITE R ZANKI S CHERNOFF D TODD J
Citation: C. Pachl et al., QUANTITATION OF HIV-1 RNA IN PLASMA USING BRANCHED DNA (BDNA) - EFFECT OF PATIENT BIOLOGIC VARIATION AND SPECIMEN MATRIX, Journal of cellular biochemistry, 1995, pp. 212-212
LACK OF ASSOCIATION BETWEEN ACYCLOVIR USE AND SURVIVAL IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE
Authors: GALLANT JE MOORE RD KERULY J RICHMAN DD CHAISSON RE BARTLETT J MCAVINUE S BRYSON Y COHEN H FISCHL M BOLIN T KESSLER H BURROUGH Y MILDVAN D FOX A RICHMAN D FREEMAN B SIMON G GRABOWY KW CHERNOFF D DUFF P THOMPSON S BARRETT K AWE R CHAPMAN R LEONARD S TURNER P HAWKINS M MURRAY H BOWERS J LANE C TILSON H ANDREWS E SMILEY L
Citation: Je. Gallant et al., LACK OF ASSOCIATION BETWEEN ACYCLOVIR USE AND SURVIVAL IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE, The Journal of infectious diseases, 172(2), 1995, pp. 346-352
CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL
Authors: KAHN JO STEIMER KS BAENZIGER J DULIEGE AM FEINBERG M ELBEIK T CHESNEY M MURCAR N CHERNOFF D SINANGIL F
Citation: Jo. Kahn et al., CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL, The Journal of infectious diseases, 171(5), 1995, pp. 1343-1347
PRIMARY ISOLATE NEUTRALIZING ACTIVITY OF HUMAN-ANTIBODIES DIRECTED TORECOMBINANT, NATIVE HIV-SF2 GP120 (RGP120(SF2))
Authors: STEIMER KS SINANGIL F KAHN J CHERNOFF D DULIEGE AM BAENZIGER J
Citation: Ks. Steimer et al., PRIMARY ISOLATE NEUTRALIZING ACTIVITY OF HUMAN-ANTIBODIES DIRECTED TORECOMBINANT, NATIVE HIV-SF2 GP120 (RGP120(SF2)), AIDS research and human retroviruses, 10, 1994, pp. 190000055-190000055
CROSS-REACTIVE NEUTRALIZING (NT) ANTIBODY (AB) INDUCED BY NATIVE HIV-1(SF-2) RGPL20
Authors: GRAHAM BS KEEFER M MCELRATH MJ SCHWARTZ D GORSE G MATTHEWS T SPOSTO R CHERNOFF D
Citation: Bs. Graham et al., CROSS-REACTIVE NEUTRALIZING (NT) ANTIBODY (AB) INDUCED BY NATIVE HIV-1(SF-2) RGPL20, AIDS research and human retroviruses, 10, 1994, pp. 190000155-190000155
ONE-YEAR FOLLOW-UP OF A PHASE-1 STUDY OF HIV-1 GP120 VACCINE COMBINEDWITH MF59 AND WITH A DOSE-ESCALATION OF MTP-PE IN HIV-1 NONINFECTED ADULTS
Authors: KAHN J CHERNOFF D SINANGIL F BAENZIGER J MURCAR N COLEMAN R WYNNE D LEE D HESTERMAN K SAKAMOTO D CUISON G DEKKER C STEIMER KS
Citation: J. Kahn et al., ONE-YEAR FOLLOW-UP OF A PHASE-1 STUDY OF HIV-1 GP120 VACCINE COMBINEDWITH MF59 AND WITH A DOSE-ESCALATION OF MTP-PE IN HIV-1 NONINFECTED ADULTS, AIDS research and human retroviruses, 10, 1994, pp. 190000155-190000155
AN AVEG PHASE-I RANDOMIZED, BLINDED, CONTROLLED TRIAL IN ASYMPTOMATICHIV-INFECTED SUBJECTS USING ENV-2-3 IN MF-59 WITH OR WITHOUT MTP-PE
Authors: COREY L MCELRATH MJ KEEFER M DOLIN R CHERNOFF D GREENBERG PD COOMBS R STEIMER K SPOSTO R
Citation: L. Corey et al., AN AVEG PHASE-I RANDOMIZED, BLINDED, CONTROLLED TRIAL IN ASYMPTOMATICHIV-INFECTED SUBJECTS USING ENV-2-3 IN MF-59 WITH OR WITHOUT MTP-PE, AIDS research and human retroviruses, 10, 1994, pp. 190000157-190000157
COMPARATIVE SAFETY AND VACCINE IMMUNOGENICITY OF YEAST-DERIVED, DENATURED, NONGLYCOSYLATED HIV-1 SF2 GP120 (ENV-2-3) VS CHO-DERIVED, CONFORMATIONALLY INTACT GLYCOSYLATED GP120 IN HIV-1 SEROPOSITIVE SUBJECTS
Authors: CHERNOFF D LANG W SINANGIL F BAENZIGER J STEINER K DEKKER C
Citation: D. Chernoff et al., COMPARATIVE SAFETY AND VACCINE IMMUNOGENICITY OF YEAST-DERIVED, DENATURED, NONGLYCOSYLATED HIV-1 SF2 GP120 (ENV-2-3) VS CHO-DERIVED, CONFORMATIONALLY INTACT GLYCOSYLATED GP120 IN HIV-1 SEROPOSITIVE SUBJECTS, AIDS research and human retroviruses, 10, 1994, pp. 190000157-190000157
SCANNING PROBE MICROSCOPY - A PRACTICAL TOOL FOR ACHIEVING QUALITY
Authors: CHERNOFF D
Citation: D. Chernoff, SCANNING PROBE MICROSCOPY - A PRACTICAL TOOL FOR ACHIEVING QUALITY, American laboratory, 26(6), 1994, pp. 41-44
CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS
Authors: KAHN JO SINANGIL F BAENZIGER J MURCAR N WYNNE D COLEMAN RL STEIMER KS DEKKER CL CHERNOFF D
Citation: Jo. Kahn et al., CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS, The Journal of infectious diseases, 170(5), 1994, pp. 1288-1291
Risultati: 1-25 | 26-31